Cargando…

Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway

Everolimus (RAD001) is a mTOR inhibitor and is widely used for the treatment of gastric cancer (GC). Evidence suggests that Rhein has anticancer effect on GC. But the synergistic effect and mechanism of RAD001 and Rhein combination on GC is not clear. The current study aims to clarify the combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Feng, Li, Rui, Wei, Pei-Feng, Ou, Li, Li, Min, Bai, Yang, Luo, Wen-Jia, Fan, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973710/ https://www.ncbi.nlm.nih.gov/pubmed/35209807 http://dx.doi.org/10.1080/21655979.2021.2005988

Ejemplares similares

Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway
por: Song, Lili, et al.
Publicado: (2022)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
por: Lin, Gigin, et al.
Publicado: (2018)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
por: Juengel, Eva, et al.
Publicado: (2009)

mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain
por: Yang, Haijuan, et al.
Publicado: (2013)

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling
por: Zhu, Dong-shan, et al.
Publicado: (2020)

Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
por: Chen, Lin, et al.
Publicado: (2019)

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
por: Maccari, Maria Elena, et al.
Publicado: (2018)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression
por: Park, Ji Hyun, et al.
Publicado: (2015)

Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway
por: Liu, Kaichao, et al.
Publicado: (2020)

Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
por: Wanigasooriya, Kasun, et al.
Publicado: (2020)

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
por: Alshaker, Heba, et al.
Publicado: (2016)

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
por: Nyfeler, Beat, et al.
Publicado: (2012)

The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior
por: Ramírez-Jarquín, Uri Nimrod, et al.
Publicado: (2020)

In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules
por: Vittorio, Serena, et al.
Publicado: (2021)

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
por: Elfiky, Aymen A, et al.
Publicado: (2011)

Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
por: Bernard, Sarah, et al.
Publicado: (2021)

Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer – A retrospective pilot analysis and viewpoint
por: Bajpai, Jyoti, et al.
Publicado: (2017)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells
por: Tai, Sheng, et al.
Publicado: (2017)

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
por: Lisi, Lucia, et al.
Publicado: (2011)

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype
por: Stengel, Chloe, et al.
Publicado: (2012)

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
por: Xia, Qin, et al.
Publicado: (2020)

Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway
por: Teng, Yong-Jie, et al.
Publicado: (2022)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
por: Alshaker, Heba, et al.
Publicado: (2017)

Phosphoinositide 3-kinase: friend and foe in cardiovascular disease
por: Ghigo, Alessandra, et al.
Publicado: (2015)

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro
por: Awad, Eman, et al.
Publicado: (2017)

Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy
por: Petherick, Katy J., et al.
Publicado: (2015)

Disrupting Reconsolidation by Systemic Inhibition of mTOR Kinase via Rapamycin Reduces Cocaine-Seeking Behavior
por: Zhang, Fushen, et al.
Publicado: (2021)

DRAM1 regulates autophagy and cell proliferation via inhibition of the phosphoinositide 3-kinase-Akt-mTOR-ribosomal protein S6 pathway
por: Lu, Ting, et al.
Publicado: (2019)

The phosphatidylinositol-3 kinase/mTOR pathway: new agents
por: Arteaga, CL
Publicado: (2011)

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009)

Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
por: Shey, Susan, et al.
Publicado: (2021)

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer
por: Scott, Kenneth L., et al.
Publicado: (2009)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma
por: Yang, Fen, et al.
Publicado: (2013)

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

Rhein Inhibits Autophagy in Rat Renal Tubular Cells by Regulation of AMPK/mTOR Signaling
por: Tu, Yue, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nrhk1b6qt7lap29s675hofqq9o